Insights

Dr Brenner, from Northwestern Medicine, discusses the current management of IBS, findings from the RELIEF phase 4 clinical trial of IBS-D, why targeting underlying pathogenic mechanisms of IBS symptoms is the future of management, and more.

Dr Harrison highlights the importance of new treatment options for patients with nonalcoholic steatohepatitis, discusses findings from the REGENERATE clinical trial presented at the ACG 2019 Annual Meeting, and more.

Dr Harrison discusses how specialists can help educate PCPs on NAFLD, the importance of PCPs recognizing which individuals with NAFLD can progress to more severe liver disease, and more.

Jessica R. Allegretti, MD, MPH, answers our questions about her study on the impact of fecal microbiota transplant from lean donors on metabolically normal people with obesity.

Dr Anderson discusses medication use during breastfeeding among women with irritable bowel syndrome (IBS), the importance of encouraging patients with IBS to continue breastfeeding, and more.

Stephen Harrison, MD, from Pinnacle Clinical Research, discusses how to educate patients on nonalcoholic fatty liver disease (NAFLD), lifestyle changes that are crucial for patients with NAFLD, and more.

Dr Harrison discusses the prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis in the United States, the correlation between NAFLD and obesity, and more.

Dr Loo and Dr Chen highlight the current management of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, obesity as a risk factor for the diseases, and more.

Dr Spergel discusses the current management of milk-induced eosinophilic esophagitis among children and his study that evaluated epicutaneous immunotherapy as a potential treatment option.